Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma

Zhao, Chang; Wang, Xu-Jie; Wang, Song; Feng, Wen; Shi, Lei; Yu, Chunpeng

doi:10.7314/apjcp.2014.15.5.2057

Cited by 8 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The randomized trial indicates that the addition of lobaplatin to the docetaxel and epirubicin regimen resulted in a significant increase in TpCR. As observed in previous studies, myelosuppression is the major dose-limiting toxicity of lobaplatin 18 , 20 , and this effect typically manifests as thrombocytopenia, anemia, and leukopenia ~2 weeks after drug administration.…”

Section: Discussionsupporting

confidence: 56%

See 1 more Smart Citation

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Tang

et al. 2018

Nat Commun

View full text Add to dashboard Cite

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3–4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.

show abstract

Section: Discussionsupporting

confidence: 56%

“…Another study of human non-small-cell lung cancer reported that the combination of lobaplatin with paclitaxel shows enhanced activity compared with cisplatin combined with paclitaxel 17 . Lobaplatin has also been shown to exhibit therapeutic efficacy in the treatment of hepatic cancer 18 , 19 , with a total effective rate of 67.6%.…”

Section: Introductionmentioning

confidence: 99%

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Tang

et al. 2018

Nat Commun

View full text Add to dashboard Cite

show abstract

“…Its use, however, is limited by sometimes severe organ toxicity, especially neuro-and nephrotoxicity. Carboplatin shows a favorable spectrum of toxicity, with reversible myelosuppression being the dose-limiting toxicity (Deng et al, 2013;Huang et al, 2013;Peng et al, 2014;Wang et al, 2014;Wu et al, 2014;Zhao et al, 2014). Especially in ovarian cancer, carboplatin appears to have equivalent activity to cisplatin.…”

Section: Discussionmentioning

confidence: 99%

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

Sun¹,

Lou²,

Sui³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Lobaplatin, one of the third -generation platinum compounds, has shown encouraging anticancer activity in a variety of tumor types. However, the efficacy of lobaplatin in ovarian cancer has not been systemically evaluated. In this study, lobaplatin as a single agent and in combination with taxanes was investigated in -vitro and in an in vitro model of ovarian carcinoma. Using the sulforhodamine B (SRB) assay, the cytotoxic effects of lobaplatin alone and in combination with taxanes were compared with cisplatin and carboplatin in seven ovarian cancer cell lines. In addition, in -vitro antitumor activities were evaluated with cisplatin -sensitive and cisplatin -resistant human ovarian cancer xenografts in nude mice. The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with IC 50 values from 0.9 to 13.8 µmol/L in a variety of ovarian cancer cells. The combination of lobaplatin with docetaxel yielded enhanced cytotoxic activity in vitro. In addition, in platinum -sensitive ovarian cancer xenografts, lobaplatin alone showed similar antitumor activity to cisplatin and carboplatin. Furthermore, lobaplatin alone or in combination with docetaxel exhibited significant activity in platinum -resistant ovarian cancer xenografts. These results indicate that the use of lobaplatin alone or in combination with docetaxel might be a rational and novel therapeutic strategy for ovarian cancer. Further clinical development of lobaplatin is clearly warranted.

show abstract

“…Zhao et al . showed [ 34 ] that Lobaplatin-based TACE is an effective and safe treatment for primary liver cancer, adverse reactions (III-IV grade) were not common, with only 4 cases of vomiting and 2 cases of thrombocytopenia (III grade). A rare side effect after TACE is an infection, which will seriously affect the recovery of patients once it occurs [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study

Zheng

Liang

et al. 2023

ACAMC

View full text Add to dashboard Cite

Purpose: To investigate the safety and efficacy of lobaplatin-TACE in the treatment of primary hepatocellular carcinoma. Method: The data of 536 patients who underwent TACE in the interventional department from January 2016 to January 2020 were collected. Patients were divided into two groups according to the chemotherapeutic drugs used in TACE.: epirubicin-TACE group(N = 260), lobaplatin-TACE group(N = 276). Primary study endpoint: (1) The tumor response after TACE; (2)The survival rates ; Secondary study endpoints:(1)Changes of liver function and blood routine before and after TACE;(2)Occurrence of post-embolization syndrome and infection after TACE. Results: The ORR was 35.0% in epirubicin-TACE group and 51.1% in lobaplatin-TACE group(P=0.001). The DCR was 73.1% in epirubicin-TACE group and 82.2% in lobaplatin-TACE group(P=0.011). The 6-month, 9-month, 12-month, and 15-month survival rates were higher in the lobaplatin-TACE group than in the epirubicin-TACE group(P=0.029,P=0.001,P=0.005,P=0.002). mOS: Epirubicin-TACE group,14.8 months; Lobaplatin-TACE group,18.6 months (P =0.007). mPFS: Epirubicin-TACE group,9.5 months; Lobaplatin-TACE group,12.8 months (P =0.000). There was no statistical difference in ALT, AST, total bilirubin and Leucocyte after TACE between the two groups (P=0.343,P=0.368,P=0.288,P=0.359). The platelet decrease after TACE was more significant in the lobaplatin-TACE group than in the epirubicin-TACE group (P=0.046). There was no statistical difference in the incidence rate of abdominal pain, fever and infection after TACE between the two groups (P=0.502,P=0.602,P=0.726).The incidence of vomiting after TACE in the lobaplatin-TACE group was higher than that in the epirubicin-TACE group (P=0.003). Conclusion: Lobaplatin-TACE has higher tumor response rate and survival rate.Lobaplatin-TACE is a safe and effective treatment strategy,it is worthy of clinical application.

show abstract

Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma

Cited by 8 publications

References 10 publications

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells

Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study

Contact Info

Product

Resources

About